TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05659901: Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

Sponsor: Ionis Pharmaceuticals, Inc. · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 32 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$1,460,800

Rescue Site Savings

+$962,800

Unlock Full NCT05659901 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05659901 Rescue Dossier →